Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy

Journal of Thoracic Oncology

Volumn 4, Issue 4, 2009, Pages 463-471

  Andersen, Sigve ^a,b   Donnem, Tom ^a,b   Al Saad, Samer ^a,b   Al Shibli, Khalid ^a,c   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

Angiogenic markers; NSCLC; Prognostic factors; Radiotherapy

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; CHEMISTRY; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349177262     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181991d18     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-936. (Pubitemid 43093958)
5. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-174. (Pubitemid 26274885)
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676. (Pubitemid 36749215)
7. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946-953. (Pubitemid 43093960)
8. Heldin CH, Eriksson U, Ostman A. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 2002;398: 284-290. (Pubitemid 34848597)
9. Waterfield MD, Scrace GT, Whittle N, et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 1983;304:35-39.
10. Doolittle RF, Hunkapiller MW, Hood LE, et al. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a plateletderived growth factor. Science 1983;221:275-277.
11. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45 Suppl 2:S163-S175. (Pubitemid 39488186)
12. Pietras K, Sjoblom T, Rubin K, et al. PDGF receptors as cancer drug targets. Cancer Cell 2003;3:439-443. (Pubitemid 38340290)
13. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-178. (Pubitemid 40616114)
14. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974. (Pubitemid 43093963)
15. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-4042.
16. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006;24:2998-3006. (Pubitemid 46638932)
17. Postoperative radiotherapy for non-small cell lung cancer. PORT Metaanalysis Trialists Group. Cochrane Database Syst Rev 2000;CD002142.
18. Sadeghi A, Payne D, Rubinstein L, et al. Combined modality treatment for resected advanced non-small cell lung cancer: local control and local recurrence. Int J Radiat Oncol Biol Phys 1988;15:89-97. (Pubitemid 18186421)
19. Slater JD, Ellerbroek NA, Barkley HT Jr, et al. Radiation therapy following resection of non-small cell bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1991;20:945-951.
20. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982;77:123-136. (Pubitemid 12162489)
21. Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002;20:2417-2428. (Pubitemid 34525727)
22. Donnem T, Al Saad S, Al Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007;13:6649-6657. (Pubitemid 350206800)
23. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427-1432. (Pubitemid 30175909)
24. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001;85:1706-1712. (Pubitemid 34081517)
25. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000;89:475-483. (Pubitemid 30947587)
26. Shikada Y, Yonemitsu Y, Koga T, et al. Platelet-derived growth factor- AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 2005;65:7241-7248. (Pubitemid 41161255)
27. Guddo F, Fontanini G, Reina C, et al. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol 1999;30:788-794. (Pubitemid 29325785)
28. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997;77:431-436. (Pubitemid 27508614)
29. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxiainducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234-2240. (Pubitemid 36687648)
30. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxiainducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-4696. (Pubitemid 30701471)
31. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
32. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59: 67-71. (Pubitemid 38501508)
33. Milosevic M, Fyles A, Hedley D, et al. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004;14:249-258. (Pubitemid 38903229)
34. Milosevic MF, Fyles AW, Wong R, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 1998;82:2418-2426. (Pubitemid 28283449)
35. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77: 18-24. (Pubitemid 41503384)
36. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934. (Pubitemid 32691937)
37. Roh HD, Boucher Y, Kalnicki S, et al. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 1991;51:6695-6698.
38. Vlahovic G, Rabbani ZN, Herndon JE, et al. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006;95:1013-1019. (Pubitemid 44606827)
39. Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006;32:348-364. (Pubitemid 44063875)
40. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-3378.
41. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-5570. (Pubitemid 30761274)
42. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-563. (Pubitemid 40017699)
43. Li J, Huang S, Armstrong EA, et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005;62:1477-1485. (Pubitemid 40982073)
44. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced longterm control of human tumor xenografts. Cancer Res 2001;61:39-44. (Pubitemid 32095696)